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Maximal treadmill exercise testing at 1, 3 and 8 hours 
was used to assess the onset, duration and antianginal 
efficacy of the dihydropyridine slow channel calcium-
blocking agent, nisoldipine, in an oral dose range of 5, 
10 and 20 mg. A double-blind, randomized, placebo-
controlled design was used involving 12 patients with 
stable effort angina. Exercise tolerance was significantly 
increased 3 hours after each dose, when the maximal 
beneficial effect occurred. The improvement was ob-
served as early as 1 hour after the 10 and 20 mg dose, 
and persisted for 8 hOlJrs after the 20 mg dose. At 3 
hours, the onset of an exercise-indpced ST segment 
depression of 0.1 m V or greater was increased by 62 
(p < 0.05), 75 (p < 0.01) and 117 seconds (p < 0.01) 
with the 5, 10 and 20 mg dose ofnisoldipine, respectively, 
Several well designed studies have shown that slow channel 
calcium-blocking drugs are effective antianginal agents in 
the medical management of both obstructive ( 1-9) and vaso-
spastic coronary artery disease (1-4,10-12), Within the di-
hydropyridine class of calcium channel blockers, nifedipine 
has been the prototypical agent whose beneficial cardio-
vascular effects in clinical and experimental myocardial 
ischemia have been extensively documenteQ, The clinical 
efficacy of nifedipine as an antianginal drug when used alone 
(1-5,10-14) or in combination with a beta-receptor block-
ing agent (15-17) has also been demonstrated, Nifedipine 
has been shown to exert favorable effects on the myocardial 
oxygen demand and supply relation (14,15,18-20), thereby 
decreasing myocardial isch~mia during exercise, 
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compared with placebo. Similarly, time to onset of an-
gina was significantly increased. The sum of exercise-
induced ST segment depression at peak exercise was 
significantly decreased (p < 0.05) from 8.7 ± 2.3 to 
6.7 ± 1.8 and 6.4 ± 2.1) mm, respectively, after the 10 
and 20 mg dose of nisoldipine. The rate-pressure product 
was significantly greater with nisoldipine than with pla-
cebo at the onset of ischemia and at peak exercise (22.8 
± 1.1 versus 20 ± 1.4 x 11)3 U for the 20 mg dose; p 
< 0.01). 
Thus, nisoldipine is an effective antianginal agent with 
a rapid onset of action that improves exercise tolerance, 
increases angina threshold and persists for at least 8 
hours after oral dosing. 
(J Am Coil Cardiol 1985;6:447-52) 
Nisoldipine, a dihydropyridine slow channel calcium 
blocker, is structurally similar to nifedipine, and has been 
shown to have a longer-lasting antihypertensive action (21) 
and to be a more potent coronary vasodilator than nifedipine 
in animal studies (22-26), However, little is known of its 
effective oral dose in human beings, its efficacy as an an-
tianginal drug and the duration of its cardiovascular effects, 
In this dose-ranging study, we compared the relative efficacy 
of a 5, 10 and 20 mg oral dose of nisoldipine on treadmill 
exercise test and hemodynamic variables, The onset and 
duration of action were detennined by three maximal ex-
ercise tests perfonned at 1, 3 and 8 hours after oral drug 
ingestion, 
Methods 
Patients. Twelve patients, with a mean age of 58 years 
(range 46 to 66), with stable angina pectoris were studied, 
All had reproducible exercise-induced angina with an as-
sociated horizontal or downsloping ST segment depression 
of 0.1 mY or greater for at least 0,08 second after the J 
point at the baseline prerandomization exercise test. Ten 
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patients were in Canadian Cardiovascular Society (27) an-
gina class 2 and two were in functional class 3. Three 
patients had a previous myocardial infarction and one patient 
had prior coronary bypass surgery. Patients who had a his-
tory of predominant rest angina or ST segment elevation 
during an episode of chest pain were excluded from the 
study as were patients who had severe hypertension, val-
vular heart disease, congestive heart failure, intraventricular 
conduction disturbances or severe ventricular arrhythmias 
on the electrocardiogram at rest. All 12 patients had a fixed 
coronary stenosis (70% or greater narrowing of luminal 
diameter) at coronary angiography; 4 patients had one vessel 
disease, 4 had two vessel disease and the remaining 4 had 
three vessel disease. The left ventricular contraction pattern 
was normal in six patients. The other six patients had wall 
motion abnormalities: five had hypokinesia and one had 
anterolateral akinesia. The ejection fraction was less than 
0.50 in one patient. 
Exercise protocol. All cardiovascular medications were 
stopped at least 48 hours before the study with the exception 
of sublingual nitroglycerin. The patients refrained from 
smoking and drinking coffee or tea, and had not taken ni-
troglycerin within 8 hours of the exercise test. Each patient 
had had at least two exercise tests before entering the study 
and was familiar with the test environment. 
The drugs were given orally at 8:00 AM and the exercise 
test was performed at 9:00 AM, 11:00 AM and 4:00 PM. A 
modified Naughton treadmill exercise protocol (28) was per-
formed; 15 electrocardiographic leads were recorded during 
and after exercise as previously described (29,30). End points 
for tenninating exercise were severe angina, dyspnea or 
extreme fatigue. Blood pressure, heart rate and the electro-
cardiogram were recorded each minute during exercise and 
for 10 minutes after exercise. The electrocardiogram was 
recorded every 20 seconds at the onset of junctional ST 
segment depression to determine as precisely as possible 
the onset of 0.1 mY of horizontal or downs loping ST seg-
ment depression. 
Study protocol. This was a double-blind, placebo-con-
trolled, randomized study comparing the short-term effects 
of a 5, 10 or 20 mg dose of oral nisoldipine on hemodynamic 
and treadmill exerc!se test variables. The exercise tests were 
performed at I, 3 and 8 hours after oral drug ingestion, 
followed by a 48 to 72 hour washout period after each trial 
of drug therapy. The series of tests, involving 4 study days 
per patient, were completed within 2 weeks for each patient. 
Treatment codes were not known until after completion of 
the study. Informed consent was obtained from each patient 
before entry into the study. 
Statistical analysis. The differences between the effects 
of placebo and the 5, 10 and 20 mg doses of oral nisoldipine 
at I, 3 and 8 hours after ingestion were analyzed by a two-
way analysis of variance. Intergroup differences were stud-
ied using a paired t test. All values are expressed as 
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mean ± SEM. The data presented in the results are 3 hour 
data unless otherwise stated. 
Results 
No significant differences from baseline value were ob-
served in heart rate, systolic blood pressure and rate-pressure 
product measured at 1, 3 or 8 hours after placebo ingestion. 
Similarly, the time to onset of 0.1 mY ST segment depres-
sion, time to onset of angina, peak exercise duration and 
extent of ST segment depression at peak exercise were not 
significantly different 1, 3 and 8 hours after placebo ingestion. 
Rest. Three hours after placebo ingestion, the heart rate 
was 66 ± 3 beats/min. The heart rate response was similar 
(68 ± 3 beats/min) after the nisoldipine dose of 5 mg, but 
was significantly increased by 8 and 7 beats/min after the 
10 and 20 mg dose, respectively (p < 0.01) (Table 1). 
Systolic blood pressure was 130 ± 4 mm Hg after pla-
cebo ingestion, and decreased by 8 (p = NS), 11 (p < 
0.05) and 14 mm Hg (p < 0.01) 3 hour& after 5, 10 and 
20 mg of nisoldipine, respectively. The systolic rate-pres-
sure product after each dose of nisoldipine did not differ 
from that after placebo as a result of the directionally op-
posing change in systolic blood pressure and heart rate. 
Submaximal exercise. Submaximal exercise heart rate 
(after 3 minutes of exercise) after placebo was 88 ± 4 
beats/min and did not change significantly after 5, 10 or 20 
mg of oral nisoldipine (89 ± 3, 92 ± 4 and 92 ± 3 
beats/min, respectively). 
Systolic blood pressure after placebo was 146 ± 5 mm 
Hg, and decreased by 7, 17 and 12 mm Hg after 5, 10 and 
20 mg of nisoldipine, respectively (p = NS). As at rest, 
the directionally opposite changes in systolic blood pressure 
and heart rate resulted in no significant change in the rate-
pressure product with all three drug doses compared with 
placebo. 
Onset of ischemia. The time to onset of exercise-
induced horizontal or downsloping ST segment depression 
of 0.1 mY or greater was significantly prolonged by all three 
doses of nisoldipine 3 hours after oral ingestion. The re-
sponse was dose-related (Fig. I). Compared with placebo, 
the increase in exercise time was greatest after the 20 mg 
dose (+ 117 seconds, p < 0.01), less with the 10 mg dose 
(+75 seconds, p < 0.01) and least with the 5 mg dose 
( + 62 seconds, p < 0.05). 
The rate-pressure product at the onset of ischemia was 
significantly greater only with the 20 mg dose of nisoldipine 
than with placebo (19.4 X 103 U ± 1.3 versus 16.2 x 
103 U ± 0.8, p < 0.01). The increase was primarily related 
to increased heart rate with no significant change in systolic 
blood pressure. 
Exercise-induced angina pectoris was abolished in two 
patients. In both, peak exercise duration was used to cal-
culate mean exercise time to angina. The mean exercise 
time to angina was significantly increased at each drug dose 
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Table l. Comparison of Nisoldipine, 5, \0 and 20 mg, With Placebo in 12 Patients at 3 Hours After Oral Ingestion 
Level of Significance 
Nisoldipine (interdrug comparison) 
Placebo 5 mg 10 mg 20 mg 5to IOmg 5 to 20 mg 10 to 20 mg 
Heart rate (beats/min) 
At rest 66 ±3 68 ± 2 74 ± 4t 73 ± 3:\: <0.05 NS NS 
Submax. exercise 88 ± 4 89 ± 3 92 ± 4 92 ± 3 NS NS NS 
Onset ST 2 0.1 mY 103 ± 4 109 ± 6* 113 ± Sf 121 ± 6+ NS 0.01 0.01 
Max. exercise 117 ± 6 130 ± 1I* 131 ±7:j: 138 ± 5:\: NS 0.05 0.05 
Systolic BP (mm Hg) 
At rest 130 ± 4 122 ± 4 119 ± 4* 116 ± 4t NS NS NS 
Submax. exercise 146 ± 5 139 ± 5 129 ± 9 134 ± 4 NS NS NS 
Onset ST 2 0.1 mY 157 ± 4 157 ± 5 155 ± 6 159 ± 4 NS NS NS 
Max. exercise 171 ± 5 170 ± 6 168 ± 6 168 ± 4 NS NS NS 
Rate-pressure product 
(X 103 U) 
At rest 8.5 ± 0.4 8.4 ± 0.3 8.9 ± 0.6 8.4 ± 0.4 NS NS NS 
Submax. exercise 12.8 ± 0.7 12.3 ± 0.6 12.4 ± 0.5 12.2 ± 0.5 NS NS NS 
Onset ST 2 0.1 mY 16.2 ± 0.8 17.1 ± 1.0 17.6 ± 1.0 19.4 ± I.3t NS 0.05 0.05 
Max. exercise 20.0 ± 1.4 22.1 ± \. 7* 22.1 ± \.5* 22.8 ± \.It NS NS NS 
Max. I ST 8.7 ± 2.3 8.6 ± 2.4 6.7 ± 1.8* 6.4 ± 2.0* 0.05 0.05 NS 
depression (mm) 
Time to onset ST 3 \0 ± 35 372 ± 35* 385 ± 44:\: 427 ± 41:\: NS 0.05 NS 
depression 2 0.1 mY 
(seconds) 
Time to angina 385 ± 47 463 ± 55* 481 ± 60t 467 ± 48:\: NS NS NS 
(seconds) 
Max. work load 442 ± 48 505 ± 54* 515 ± 59:\: 535 ± 44t NS NS NS 
(seconds) 
Yalues are mean ± SEM. Placebo vs. drug: *p < 0.05; tp < 0.01; :\:p < 0.001. BP = blood pressure; Max. = maximal; NS = not significant; 
Submax. = submaximal; L = sum. 
compared with placebo, the increase being 78 (p < 0.05), 
96 (p < 0.01) and 82 seconds (p < 0.0 I) with the 5, lO 
and 20 mg dose, respectively. 
Figure l. The time to onset of exercise-induced ST segment 
depression (STD) of 0.1 mV or greater, angina threshold and peak 
exercise work load were significantly increased 3 hours after ni-
soldipine ingestion. The increase was significant in each dose 
range. VIS = versus. 
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The rate-pressure product at angina threshold was in-
creased by each drug dose. The increase was significant 
only at 3 hours and was 2.1 X 103 (p < 0.05), 2.6 x lO3 
(p < 0.05) and 1.9 x lO3 U (p < 0.05) with the 5, lO and 
20 mg dose of nisoldipine. 
Maximal exercise. Peak exercise tolerance was pro-
longed by each drug. The response was dose-related with 
the 20 mg dose resulting in the greatest increase in exercise 
duration of 93 seconds (p < 0.0 I); the 5 and lO mg dose 
produced an increase of 63 (p < 0.05) and 73 (p < 0.0 I) 
seconds, respectively (Fig. 2). 
The relative tachycardia induced by nisoldipine at rest 
was maintained throughout the exercise period, with an 
average heart rate increase of 13, 14 and 18 beats/min 
(p < 0.01) for the 5, 10 and 20 mg dose, respectively. 
Systolic blood pressure was unchanged compared with that 
of placebo. Consequently, the respective increase in rate-
pressure product of 2.1 x lO3 (p < 0.05), 2.1 x lO3 
(p < 0.05) and 2.8 x 103 U (p < 0.01) at peak exercise 
for the 5, 10 and 20 mg dose was mainly due to the increase 
in heart rate (Table I). The augmentation of heart rate and 
rate-pressure product at peak exercise was associated with 
an increased work performance. 
The sum of ST segment depression in the J 5 electrocar-
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Figure 2. The maximal increase in exercise tolerance (exercise 
duration) occurred at 3 hours. The benefit was dose-related and 
occurred as early as I hour after JO to 20 mg of nisoldipine and 
persisted for 8 hours after 20 mg of nisoldipine administration. 
VIS = versus. 
diographic leads at peak exercise was significantly less after 
the administration of 10 and 20 mg of nisoldipine than with 
placebo (p < 0.05) (Table 1). However, 3 hours after the 
drug was taken, conversion to a negative electrocardiogram 
(ST segment depression <0.1 mY in any lead) did not occur 
in any patient. 
Temporal drug effect. The effect of the 5 mg dose of 
nisoldipine on heart rate, systolic blood pressure and rate-
pressure product at rest was not significantly different from 
the effect of placebo I, 3 and 8 hours after drug ingestion. 
Figure 3. One hour after nisoldipine administration, the time to 
onset of exercise-induced ST segment depression (STD) of 0.1 
m V or greater and angina threshold were significantly increased 
after the JO mg dose. Peak exercise tolerance (exercise duration) 
was significantly (p < 0.05) improved by the JO and 20 mg dose. 
VIS = versus. 
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Figure 4. Eight hours after nisoldipine administration, only the 
20 mg dose had a persistent beneficial anti anginal effect. x ± 
SEM = mean ± standard error of the mean; other abbreviations 
as in Figure 3. 
The 10 mg dose of nisoldipine significantly increased heart 
rate compared with placebo to a similar degree 1 and 3 
hours after administration although the effect was largely 
dissipated at 8 hours. The significant increase in heart rate 
and decrease in systolic blood pressure observed at 3 hours 
after the 20 mg dose of nisoldipine remained significantly 
different from the values with placebo 8 hours after drug 
administration although the magnitude of change was less 
marked. 
Improvement in peak exercise duration was maximal at 
3 hours for each dose of nisoldipine (Fig. 2) and was dose-
related, with the 20 mg dose producing the greatest benefit. 
The onset of action occurred as early as 1 hour (Fig. 3) after 
drug ingestion and lasted for 8 hours after the 20 mg dose 
was ingested (Fig. 4). The 5 mg dose was ineffective at 1 
and 8 hours. 
In contrast to the 3 hour results, the sum of ST segment 
depression in the 15 electrocardiographic leads at peak ex-
ercise was similar to values with placebo at 1 and 8 hours 
for each dose of nisoldipine. 
Discussion 
Nisoldipine, a new dihydropyridine slow channel cal-
cium blocker, has been shown in experimental animals (23-26) 
to have a longer duration of antihypertensive action and to 
be a more potent coronary vasodilator with less negative 
inotropic properties than its structural analog, nifedipine. 
Thus, nisoldipine may have the potential to be a useful 
antianginal agent. However, there is little documentation of 
either its clinical efficacy as an antianginal agent in human 
beings or its effective oral dose and duration of action. 
Effect on test exercise variables. In this placebo-con-
trolled, double-blind, randomized study, we have shown 
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that after oral administration of a single dose, nisoldipine 
produced a significant improvement in exercise tolerance in 
patients with stable effort angina and angiographically doc-
umented obstructive coronary artery disease, The improve-
ment in exercise tolerance was indicated not only by a sig-
nificant prolongation of the time to onset of angina and 
abolition of exercise-induced angina in two patients, but 
also by a significant increase in peak exercise capacity and 
a delayed appearance of electrocardiographic signs of myo-
cardial ischemia, The salutary effects on exercise test vari-
ables were noted as early as 1 hour after oral administration 
of a single 10 or 20 mg dose; no significant effects were 
noted with the 5 mg dose, Maximal drug efficacy was noted 
at 3 hours after drug ingestion in a dose-related manner with 
the 20 mg dose having the most beneficial effect. Improve-
ment in exercise variables were significant for 8 hours after 
the 20 mg dose only. 
Hemodynamic effect. The hemodynamic effects in-
cluded an 11 % increase in heart rate at rest, similar to that 
previously reported (22), The tachycardia effect was evident 
as early as I hour and still present at 3 hours but not observed 
at 8 hours after drug ingestion. Systolic blood pressure de-
creased by approximately 10%, within the range of previ-
ously reported values (22). The decrease was noted at 3 
hours and persisted to 8 hours for the 20 mg dose, supporting 
previous observations in dogs of an antihypertensive effect 
lasting up to 12 hours after oral drug usage (21). The de-
crease in blood pressure was not evident during exercise 
even when there was a persistent tachycardia effect. 
The hemodynamic effect as well as the improvement in 
exercise variables at 8 hours after a 20 mg dose of nisol-
dipine are in contrast to previously reported effects of a 20 
mg dose of nifedipine using a similar protocol (5) in which 
the latter produced no discernible benefit at 8 hours after 
oral dosing. This may be a clinically significant observation, 
in that nisoldipine may require less frequent dosing to main-
tain a beneficial anti anginal effect. Comparison of the two 
drugs in the same patient group would be of interest. The 
results of this short-term dose study may not be extrapolated 
to long-term therapy in which the possibilities of drug ac-
cumulation, tolerance and interactions may playa role. 
Antianginal mechanism. High-dose nisoldipine de-
creased systolic blood pressure and increased heart rate with-
out changing rest or submaximal rate-pressure product. The 
constancy of the rate-pressure product, an indirect measure 
of myocardial oxygen demand (31), at rest and during sub-
maximal exercise suggests that reduction of myocardial ox-
ygen demand is not the only mechanism of action of this 
drug. The delayed appearance of myocardial ischemia and 
prolonged exercise capacity (Fig. 1), both accompanied by 
a higher rate-pressure product, suggests that the predomi-
nant antianginal mechanism of nisoldipine may be to in-
crease coronary blood flow to potentially ischemic myo-
cardium. This hypothesis is supported by the fact that 
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electrocardiographic manifestations of exercise-induced 
myocardial ischemia were significantly decreased at higher 
peak work loads, and by other data which have shown an 
increase in total as well as collateral coronary blood flow 
to ischemic myocardium in experimental animals pretreated 
with nisoldipine (22,26). The mechanisms of action are 
similar to nifedipine (18-20), although nisoldipine is re-
ported to be a more potent and selective coronary vasodilator 
(22,23,26). 
Clinical implications. Nisoldipine is an effective an-
tianginal drug. Longer-term studies are required to docu-
ment its long-term efficacy and safety and to evaluate its 
beneficial effects relative to beta-receptor blockers and other 
slow channel calcium blockers. It would appear from this 
short-term dose study that 10 to 20 mg of nisoldipine may 
be necessary to produce an "optimal" antianginal effect 
and that the drug will not require more than two or three 
doses daily. The antianginal benefit of nisoldipine would 
most likely be potentiated by the use of beta-adrenergic 
blocking drugs that would blunt the reflex tachycardia in-
duced by this dihydropyridine derivative. 
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